JAKs and STATs in Immunity, Immunodeficiency, and Cancer

STATs in cancer inflammation and immunity: a leading role for STAT3

Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

James, C., Ugo, V., Couedic, J. P. L., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslová, H., Berger, R., Griscelli, A. B., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,542

A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470

A Genome-Wide Association Study Identifies IL23R as an Inflammatory Bowel Disease Gene

Duerr, R. H., Taylor, K. D., Brant, S. R., Rioux, J. D., Silverberg, M. S., Daly, M. J., Steinhart, A. H., Abraham, C., Regueiro, M., Griffiths, A., et al. (2006) · Science · doi:10.1126/science.1135245 · Cited by 3,039

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103

JAKS AND STATS: Biological Implications

Leonard, W. J., & O’Shea, J. J. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.293 · Cited by 1,826

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596

Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS‐CoV‐2 Vaccination: A Systematic Review

Mussi, M., Zengarini, C., Corrà, A., Brunetti, T., Natale, A., Plaça, M. L., Piraccini, B. M., Guglielmo, A., & Pileri, A. (2026) · Journal of Skin Cancer · doi:10.1155/jskc/4893577

A Novel IFIH1 Mutation Causing Hyper‐ IgE Syndrome Presenting as Childhood Erythroderma: Case Report

Belgaumkar, V., Bhatia, S., Tolat, S., & Pradhan, S. (2026) · Pediatric Dermatology · doi:10.1111/pde.70274

The minor spliceosome component U4atac regulates JAK/STAT signaling to modulate hematopoiesis and immune responses in Drosophila melanogaster

Shikara, D., Bishop, E., Barton, N., Makdissi, S., Kailasam, S., György, A., Siekhaus, D. E., Borroto, M. C., Campeau, P. M., Vong, L., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75539-y

Respiratory microbiome dysbiosis in STAT3 hyper-IgE syndrome (Job syndrome)

Roca, C., Greenwald, M. A., Zorn, B., Sun, L., Chen, G., Freeman, A. F., Boucher, R. C., Olivier, K. N., & Wolfgang, M. C. (2026) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-026-04508-x

Immunopathogenesis of itch: an integrative framework for chronic pruritus

Kaczmarska, A., & Reich, A. (2026) · JID Innovations · doi:10.1016/j.xjidi.2026.100517

Why JAK3 selectivity matters: biology, approved JAK inhibitors, and medicinal chemistry perspectives

da Silva, S. D., & Parise-Filho, R. (2026) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2026.110298

Immunomodulatory and anti-inflammatory potential of S-nitrosoglutathione (GSNO) in multiple sclerosis: a review of mechanisms and therapeutic perspectives

Won, J., Kim, J., Singh, A. K., & Singh, I. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1797609

Neutrophil-intrinsic Vgll4 constrains tumorigenesis by preventing a STAT3/STAT5-driven immunosuppressive switch

Shao, L., Yue, J., Wang, S., Yu, R., Cheng, S., Nie, P., Jiang, X., Han, Y., Wang, W., Meng, Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2606983123

Case Report: STAT3 hyper-IgE syndrome in children: two cases report with uncommon complications of tuberculosis and lymphoma

Cao, X., Wang, B., & Xu, Y. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1872306

Emerging CCR5-Based Therapeutic Potential of JAK/STAT Inhibitors and CCR5Δ32 Hematopoietic Stem Cell Transplantation

Khalid, K., Iqbal, U., Shaltout, M., Yükselten, Y., Ahmad, F., Khalid, A. R., & Sutton, R. E. (2026) · Viruses · doi:10.3390/v18090933

Adaptive bandwidth of immunity: a systems-level framework for understanding immune regulation across time

Ionitescu, R. C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1848870

JAK inhibitors and adverse cardiovascular events: Class effect or molecule-specific risk?

Radić, M., Bečić, T., Šimac, P., Pavlović, M. R., Vučković, M., Radić, J., Borovac, J. A., Fajkić, A., & Belančić, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1896980

TRPV1–STAT3 signaling as a driver of lethal pathology during pneumococcal nose-to-brain invasion

Sakatani, H., Ueda, R., Kono, M., Fujishiro, T., Hijiya, M., Morita, Y., Kawabata, K., Okada, T., Mizobata, K., Saika, S., et al. (2026) · Microbiology Spectrum · doi:10.1128/spectrum.01320-26

Therapeutic approaches for inflammation: Focus on acute and chronic phases, investigational therapies, and disease monitoring

Shilpashree, H. P., Anupama, S. K., Roopashri, A. N., & Deepashree, H. P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33887-8.00010-6

EGCG targeting JAK1/ STAT5 or STAT6 dampens pseudorabies virus replication via inhibiting BNIP3/caspase-3-dependent apoptosisPreprint

Huan, C., Xu, W., Cheng, J., Wang, J., Yan, P., Jiang, L., & Gao, S. (2026) · Research Square · doi:10.21203/rs.3.rs-10749480/v1

Targeting receptor tyrosine kinases: from molecular mechanisms to clinical therapeutics

Wu, K., Ji, J., Sun, T., Lv, D., Pan, J., Wei, M., Zhu, M., Wang, M., Li, L., & Yao, H. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02840-z

BindingDB Entry 50001017: Discovery of potent and efficacious pyrrolopyridazines as dual JAK1/3 inhibitors.

BindingDB (2020) · UC San Diego · doi:10.7270/q2g73h7v

BindingDB Entry 50019450: Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.

BindingDB (2024) · UC San Diego · doi:10.7270/q2c82fpw

BindingDB Entry 50017511: Identification of TUL01101: A Novel Potent and Selective JAK1 Inhibitor for the Treatment of Rheumatoid Arthritis.

BindingDB (2023) · UC San Diego · doi:10.7270/q2bz6b4k

BindingDB Entry 50016738: Conversion of a False Virtual Screen Hit into Selective JAK2 JH2 Domain Binders Using Convergent Design Strategies.

BindingDB (2023) · UC San Diego · doi:10.7270/q2q52tn2

BindingDB Entry 50020220: Progress on the Pharmacological Targeting of Janus Pseudokinases.

BindingDB (2024) · UC San Diego · doi:10.7270/q2d50sch

BindingDB Entry 50048066: Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors.

BindingDB (2018) · UC San Diego · doi:10.7270/q21z46ch

BindingDB Entry 50044830: Triazolopyridines as selective JAK1 inhibitors: from hit identification to GLPG0634.

BindingDB (2016) · UC San Diego · doi:10.7270/q2gh9kk6

BindingDB Entry 50007541: Discovery of potent anti-inflammatory 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl) pyrimidin-2-amines for use as Janus kinase inhibitors.

BindingDB (2021) · UC San Diego · doi:10.7270/q25d8w5b

BindingDB Entry 50009333: Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease.

BindingDB (2021) · UC San Diego · doi:10.7270/q2h135fn

BindingDB Entry 50006204: Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.

BindingDB (2020) · UC San Diego · doi:10.7270/q28g8pp6

BindingDB Entry 50020358: Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.

BindingDB (2024) · UC San Diego · doi:10.7270/q2qz2gf5

BindingDB Entry 50020672: Development and Therapeutic Implications of Tyrosine Kinase 2 Inhibitors.

BindingDB (2024) · UC San Diego · doi:10.7270/q2bp0783

BindingDB Entry 50022952: Recent advances in the design of small molecular drugs with acrylamides covalent warheads.

BindingDB (2026) · UC San Diego · doi:10.7270/q2rv0tkm

BindingDB Entry 50008015: Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.

BindingDB (2021) · UC San Diego · doi:10.7270/q2mw2mh3

BindingDB Entry 50016591: Covalent Modification of the JH2 Domain of Janus Kinase 2.

BindingDB (2023) · UC San Diego · doi:10.7270/q2d50rzq

BindingDB Entry 50022995: Design of a potent and selective dual JAK1/TYK2 inhibitor.

BindingDB (2026) · UC San Diego · doi:10.7270/q2qn6cmk

BindingDB Entry 50009360: Discovery of (2

BindingDB (2021) · UC San Diego · doi:10.7270/q21v5jdf

BindingDB Entry 50015895: Small molecules targeting cGAS-STING pathway for autoimmune disease.

BindingDB (2023) · UC San Diego · doi:10.7270/q2k35zmg

BindingDB Entry 50016770: Insights on JAK2 Modulation by Potent, Selective, and Cell-Permeable Pseudokinase-Domain Ligands.

BindingDB (2023) · UC San Diego · doi:10.7270/q21g0r8f

BindingDB Entry 50000252: Identification and Characterization of JAK2 Pseudokinase Domain Small Molecule Binders.

BindingDB (2019) · UC San Diego · doi:10.7270/q29g5q7z

BindingDB Entry 50002581: Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.

BindingDB (2020) · UC San Diego · doi:10.7270/q2n58q0z

BindingDB Entry 50011143: Discovery and optimization of 2-aminopyridine derivatives as novel and selective JAK2 inhibitors.

BindingDB (2021) · UC San Diego · doi:10.7270/q2028w4w

BindingDB Entry 50022580: Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases.

BindingDB (2025) · UC San Diego · doi:10.7270/q20c51hf

A pectic polysaccharide from Lonicera japonica alleviates DNCB-induced atopic dermatitis-like inflammation associated with gut microbial and metabolic alterations and reduced cutaneous JAK2/STAT3 activation and Th17 responses

Jin, M., Hu, Y., Ding, M., Cheng, J., 刘美池, Liu, X., Bai, X., & Fan, X. (2026) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2026.122553

Twist1 and Etv5 are part of a transcription factor network defining T helper cell identity

Pham, D. (2014) · doi:10.7912/c2/1727

Patogenia de las neoplasias mieloproliferativas

Martínez‐López, J., Barrio, S., & Díaz, R. A. (2013) · Elsevier eBooks · doi:10.1016/b978-84-9022-648-3.50005-2

JAKs—STATs信号传导——疾病治疗新领域

Ping, Z. X. (2001) · 国外医学（免疫学分册）

004 JAKs-STATs信号传导--疾病治疗新领域

Ping, Z. X., & 吴慧君 (2001) · 国外医学（免疫学分册） · doi:10.3760/cma.j.issn.1673-4394.2001.01.004

Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

Chen, X., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 797

JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences

Ott, N., Faletti, L. E., Heeg, M., Andreani, V., & Grimbacher, B. (2023) · Journal of Clinical Immunology · doi:10.1007/s10875-023-01483-x · Cited by 87

Immunodeficiency: Consequences of Mutations in JAK-STAT Signaling

Silberger, D. J., & Pham, D. (2020) · CRC Press eBooks · doi:10.1201/9781351042468-13 · Cited by 1